MTCYBP40

Across TCGA pan-cancer cohorts, MTCYBP40 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MTCYBP40 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher MTCYBP40 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCYBP40 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LAML show a favorable association.

PAAD, DLBC, and BLCA are the cancer types where MTCYBP40 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.254	0.620	<.001	90	view →
DLBC	DFS	Tertile	All	0.338	0.795	.010	64	view →
BLCA	DFS	Tertile	All	0.412	0.633	.015	45	view →
BRCA	DFS	Tertile	IV	0.175	0.730	.005	36	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
OV	OS	Tertile	IV	0.319	0.644	.017	30	view →
SKCM	DFS	Tertile	III,IV	1.000	0.463	.016	24	view →
LUSC	OS	Tertile	All	0.187	0.515	.020	18	view →
LAML	DFS	Tertile	All	0.595	0.314	.027	12	view →
COAD	DFS	Tertile	II,III,IV	0.239	0.652	.013	9	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.239	.046	9	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MTCYBP40–PAAD (OS)

Open the PAAD breakdown →